Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 0.77 |
| ▸ | GHSR | Q92847 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20768982 | 1.00 | SMYD3 (0.77) | SMYD3GHSRMAPTSMN1; SMN2HTT | |
| SCHEMBL20768936 | 1.00 | SMYD3 (0.77) | SMYD3GHSRMAPTSMN1; SMN2HTT | |
| SCHEMBL20768911 | 0.93 | SMYD3 (0.67) | SMYD3GHSRMAPTSMN1; SMN2HTT | |
| SCHEMBL20768913 | 0.93 | SMYD3 (0.67) | SMYD3GHSRMAPTSMN1; SMN2HTT | |
| SCHEMBL20769146 | 0.92 | SMYD3 (0.71) | SMYD3GHSRHTTL3MBTL1 | |
| SCHEMBL20768898 | 0.92 | SMYD3 (0.71) | SMYD3GHSRHTTL3MBTL1 | |
| SCHEMBL20768899 | 0.92 | SMYD3 (0.71) | SMYD3GHSRHTTL3MBTL1 | |
| SCHEMBL20768816 | 0.92 | SMYD3 (0.66) | SMYD3GHSRMAPTSMN1; SMN2HPGD | |
| SCHEMBL20769121 | 0.92 | SMYD3 (0.66) | SMYD3GHSRMAPTSMN1; SMN2HTT | |
| SCHEMBL20769120 | 0.92 | SMYD3 (0.66) | SMYD3GHSRMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | SMYD3 1/4885GHSR 2173/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.